E-Mail
IMAGE: Representative maximum intensity projection PET/CT images of AR42J tumor-bearing female Balb/c nude mice following injection of 64Cu-CuSarTATE (3 MBq, 0.24 nmol of peptide) at 1 and 4 hours post injection.. view more
Credit: Images created by associate professor Carleen Cullinane (Peter MaCallum Cancer Centre).
Reston, Virginia A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival. According to new research published in the December issue of
The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan. The research also demonstrated the advantages of delivering the radionuclide therapy as two fractionated
Date Time
New Theranostic Approach Reduces Tumor Volume and Increases Survival in Neuroendocrine Tumor Study
Reston, Virginia-A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival. According to new research published in the December issue of The Journal of Nuclear Medicine, the imaging agent
64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart,
67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan. The research also demonstrated the advantages of delivering the radionuclide therapy as two fractionated doses, as opposed to one.